Compile Data Set for Download or QSAR
Report error Found 2749 Enz. Inhib. hit(s) with Target = 'GTPase KRas [G12C]'
TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM717622(US20250034173, Example 13)
Affinity DataKd:  0.0170nMAssay Description:Binding measurements were performed in parallel sets of either WT/G12D/G12C/G12V KRAS or WT K/H/N RAS proteins in GDP and/or GTPγS-loaded forms.Biaco...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM717614(US20250034173, Example 2)
Affinity DataKd:  0.0190nMAssay Description:Binding measurements were performed in parallel sets of either WT/G12D/G12C/G12V KRAS or WT K/H/N RAS proteins in GDP and/or GTPγS-loaded forms.Biaco...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM706700(US20240383922, Example 22-2)
Affinity DataIC50: 0.0200nMAssay Description:Compounds were tested for binding to GDP-loaded wild-type KRAS (WT), KRAS-G12C, KRAS-G12D, and KRAS-G12V in a 384-well assay format using a TR-FRET p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM717613((General Method A): (8aS)-5-(6-chloro-5-cyclopropy...)
Affinity DataKd:  0.0310nMAssay Description:Binding measurements were performed in parallel sets of either WT/G12D/G12C/G12V KRAS or WT K/H/N RAS proteins in GDP and/or GTPγS-loaded forms.Biaco...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM706670(US20240383922, Example 6-23)
Affinity DataIC50: 0.0500nMAssay Description:Compounds were tested for binding to GDP-loaded wild-type KRAS (WT), KRAS-G12C, KRAS-G12D, and KRAS-G12V in a 384-well assay format using a TR-FRET p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM717620(US20250034173, Example 11)
Affinity DataKd:  0.0510nMAssay Description:Binding measurements were performed in parallel sets of either WT/G12D/G12C/G12V KRAS or WT K/H/N RAS proteins in GDP and/or GTPγS-loaded forms.Biaco...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM706658(US20240383922, Example 6-11)
Affinity DataIC50: 0.0510nMAssay Description:Compounds were tested for binding to GDP-loaded wild-type KRAS (WT), KRAS-G12C, KRAS-G12D, and KRAS-G12V in a 384-well assay format using a TR-FRET p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM706660(US20240383922, Example 6-13)
Affinity DataIC50: 0.0600nMAssay Description:Compounds were tested for binding to GDP-loaded wild-type KRAS (WT), KRAS-G12C, KRAS-G12D, and KRAS-G12V in a 384-well assay format using a TR-FRET p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM706683(US20240383922, Example 9-2)
Affinity DataIC50: 0.0600nMAssay Description:Compounds were tested for binding to GDP-loaded wild-type KRAS (WT), KRAS-G12C, KRAS-G12D, and KRAS-G12V in a 384-well assay format using a TR-FRET p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM706661(US20240383922, Example 6-14)
Affinity DataIC50: 0.0800nMAssay Description:Compounds were tested for binding to GDP-loaded wild-type KRAS (WT), KRAS-G12C, KRAS-G12D, and KRAS-G12V in a 384-well assay format using a TR-FRET p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM706666(US20240383922, Example 6-19)
Affinity DataIC50: 0.0900nMAssay Description:Compounds were tested for binding to GDP-loaded wild-type KRAS (WT), KRAS-G12C, KRAS-G12D, and KRAS-G12V in a 384-well assay format using a TR-FRET p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM706701(US20240383922, Example 22-3)
Affinity DataIC50: 0.110nMAssay Description:Compounds were tested for binding to GDP-loaded wild-type KRAS (WT), KRAS-G12C, KRAS-G12D, and KRAS-G12V in a 384-well assay format using a TR-FRET p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM717621(US20250034173, Example 12)
Affinity DataKd:  0.122nMAssay Description:Binding measurements were performed in parallel sets of either WT/G12D/G12C/G12V KRAS or WT K/H/N RAS proteins in GDP and/or GTPγS-loaded forms.Biaco...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM706651(US20240383922, Example 4-2)
Affinity DataIC50: 0.180nMAssay Description:Compounds were tested for binding to GDP-loaded wild-type KRAS (WT), KRAS-G12C, KRAS-G12D, and KRAS-G12V in a 384-well assay format using a TR-FRET p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM706690(US20240383922, Example 16-2)
Affinity DataIC50: 0.190nMAssay Description:Compounds were tested for binding to GDP-loaded wild-type KRAS (WT), KRAS-G12C, KRAS-G12D, and KRAS-G12V in a 384-well assay format using a TR-FRET p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM706665(US20240383922, Example 6-18)
Affinity DataIC50: 0.190nMAssay Description:Compounds were tested for binding to GDP-loaded wild-type KRAS (WT), KRAS-G12C, KRAS-G12D, and KRAS-G12V in a 384-well assay format using a TR-FRET p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM706691(US20240383922, Example 16-3)
Affinity DataIC50: 0.320nMAssay Description:Compounds were tested for binding to GDP-loaded wild-type KRAS (WT), KRAS-G12C, KRAS-G12D, and KRAS-G12V in a 384-well assay format using a TR-FRET p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM706664(US20240383922, Example 6-17)
Affinity DataIC50: 0.370nMAssay Description:Compounds were tested for binding to GDP-loaded wild-type KRAS (WT), KRAS-G12C, KRAS-G12D, and KRAS-G12V in a 384-well assay format using a TR-FRET p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM706692(US20240383922, Example 17-1)
Affinity DataIC50: 0.380nMAssay Description:Compounds were tested for binding to GDP-loaded wild-type KRAS (WT), KRAS-G12C, KRAS-G12D, and KRAS-G12V in a 384-well assay format using a TR-FRET p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM706693(US20240383922, Example 17-2)
Affinity DataIC50: 0.490nMAssay Description:Compounds were tested for binding to GDP-loaded wild-type KRAS (WT), KRAS-G12C, KRAS-G12D, and KRAS-G12V in a 384-well assay format using a TR-FRET p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM663069(2-((2S)-4-(8-fluoro-2- ((S)-1-methylpyrrolidin- 2-...)
Affinity DataIC50: 0.490nMAssay Description:1. Serially 4×-diluted compounds (10 concentration points in total) were separately premixed with KRAS G12C-GDP (ICE, Kras 20191018) in a reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM706695(US20240383922, Example 18-2)
Affinity DataIC50: 0.490nMAssay Description:Compounds were tested for binding to GDP-loaded wild-type KRAS (WT), KRAS-G12C, KRAS-G12D, and KRAS-G12V in a 384-well assay format using a TR-FRET p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM706668(US20240383922, Example 6-21)
Affinity DataIC50: 0.540nMAssay Description:Compounds were tested for binding to GDP-loaded wild-type KRAS (WT), KRAS-G12C, KRAS-G12D, and KRAS-G12V in a 384-well assay format using a TR-FRET p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM706675(US20240383922, Example 7-5)
Affinity DataIC50: 0.550nMAssay Description:Compounds were tested for binding to GDP-loaded wild-type KRAS (WT), KRAS-G12C, KRAS-G12D, and KRAS-G12V in a 384-well assay format using a TR-FRET p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM663067(2-((2S)-4-(8-fluoro-2- ((2R,7aS)-2- fluorotetrahyd...)
Affinity DataIC50: 0.590nMAssay Description:1. Serially 4×-diluted compounds (10 concentration points in total) were separately premixed with KRAS G12C-GDP (ICE, Kras 20191018) in a reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM663064(US20240109893, Example 854)
Affinity DataIC50: 0.590nMAssay Description:1. Serially 4×-diluted compounds (10 concentration points in total) were separately premixed with KRAS G12C-GDP (ICE, Kras 20191018) in a reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM706707(US20240383922, Example 23-1)
Affinity DataIC50: 0.640nMAssay Description:Compounds were tested for binding to GDP-loaded wild-type KRAS (WT), KRAS-G12C, KRAS-G12D, and KRAS-G12V in a 384-well assay format using a TR-FRET p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM706706(US20240383922, Example 22-8)
Affinity DataIC50: 0.670nMAssay Description:Compounds were tested for binding to GDP-loaded wild-type KRAS (WT), KRAS-G12C, KRAS-G12D, and KRAS-G12V in a 384-well assay format using a TR-FRET p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM663066(2-((2S)-1-acryloyl-4-(8- fluoro-2-((2R,7aS)-2- flu...)
Affinity DataIC50: 0.710nMAssay Description:1. Serially 4×-diluted compounds (10 concentration points in total) were separately premixed with KRAS G12C-GDP (ICE, Kras 20191018) in a reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM663068(2-((2S)-1-acryloyl-4- (8-fluoro-2-((S)-1- methylpy...)
Affinity DataIC50: 0.710nMAssay Description:1. Serially 4×-diluted compounds (10 concentration points in total) were separately premixed with KRAS G12C-GDP (ICE, Kras 20191018) in a reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM706697(US20240383922, Example 20-1)
Affinity DataIC50: 0.740nMAssay Description:Compounds were tested for binding to GDP-loaded wild-type KRAS (WT), KRAS-G12C, KRAS-G12D, and KRAS-G12V in a 384-well assay format using a TR-FRET p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM663065(2-((2S)-1-acryloyl-4- (8-fluoro-2-((S)-1- methylpy...)
Affinity DataIC50: 0.790nMAssay Description:1. Serially 4×-diluted compounds (10 concentration points in total) were separately premixed with KRAS G12C-GDP (ICE, Kras 20191018) in a reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM706677(US20240383922, Example 7-7)
Affinity DataIC50: 0.850nMAssay Description:Compounds were tested for binding to GDP-loaded wild-type KRAS (WT), KRAS-G12C, KRAS-G12D, and KRAS-G12V in a 384-well assay format using a TR-FRET p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM663072(2-((S)-4-(7-(8- chloronaphthalen-1- yl)-8-fluoro- ...)
Affinity DataIC50: 0.890nMAssay Description:1. Serially 4×-diluted compounds (10 concentration points in total) were separately premixed with KRAS G12C-GDP (ICE, Kras 20191018) in a reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM717618(US20250034173, Example 6)
Affinity DataKd:  0.894nMAssay Description:Binding measurements were performed in parallel sets of either WT/G12D/G12C/G12V KRAS or WT K/H/N RAS proteins in GDP and/or GTPγS-loaded forms.Biaco...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM706673(US20240383922, Example 7-1)
Affinity DataIC50: 0.900nMAssay Description:Compounds were tested for binding to GDP-loaded wild-type KRAS (WT), KRAS-G12C, KRAS-G12D, and KRAS-G12V in a 384-well assay format using a TR-FRET p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM706682(US20240383922, Example 8-3)
Affinity DataIC50: 0.910nMAssay Description:Compounds were tested for binding to GDP-loaded wild-type KRAS (WT), KRAS-G12C, KRAS-G12D, and KRAS-G12V in a 384-well assay format using a TR-FRET p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM706659(US20240383922, Example 6-12)
Affinity DataIC50: 0.920nMAssay Description:Compounds were tested for binding to GDP-loaded wild-type KRAS (WT), KRAS-G12C, KRAS-G12D, and KRAS-G12V in a 384-well assay format using a TR-FRET p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM663073(2-((S)-4-(7-(8- chloronaphthalen-1- yl)-8-fluoro- ...)
Affinity DataIC50: 0.930nMAssay Description:1. Serially 4×-diluted compounds (10 concentration points in total) were separately premixed with KRAS G12C-GDP (ICE, Kras 20191018) in a reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM717666(US20250034173, Example 54)
Affinity DataKd: <1nMAssay Description:Binding measurements were performed in parallel sets of either WT/G12D/G12C/G12V KRAS or WT K/H/N RAS proteins in GDP and/or GTPγS-loaded forms.Biaco...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM743470(N-[(1S)-1-[[(8S,14S)-22-ethyl-4-hydroxy-(21M)-21-[...)
Affinity DataIC50: 1nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM717641(US20250034173, Example 29)
Affinity DataKd:  1nMAssay Description:Binding measurements were performed in parallel sets of either WT/G12D/G12C/G12V KRAS or WT K/H/N RAS proteins in GDP and/or GTPγS-loaded forms.Biaco...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM717638(US20250034173, Example 26)
Affinity DataKd:  1nMAssay Description:Binding measurements were performed in parallel sets of either WT/G12D/G12C/G12V KRAS or WT K/H/N RAS proteins in GDP and/or GTPγS-loaded forms.Biaco...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM717665(US20250034173, Example 53)
Affinity DataKd:  1nMAssay Description:Binding measurements were performed in parallel sets of either WT/G12D/G12C/G12V KRAS or WT K/H/N RAS proteins in GDP and/or GTPγS-loaded forms.Biaco...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM717674(US20250034173, Example 62)
Affinity DataKd: <1nMAssay Description:Binding measurements were performed in parallel sets of either WT/G12D/G12C/G12V KRAS or WT K/H/N RAS proteins in GDP and/or GTPγS-loaded forms.Biaco...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM717667(US20250034173, Example 55)
Affinity DataKd:  1nMAssay Description:Binding measurements were performed in parallel sets of either WT/G12D/G12C/G12V KRAS or WT K/H/N RAS proteins in GDP and/or GTPγS-loaded forms.Biaco...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM663070(2-((2S)-4-(8-fluoro-2- ((2R,7aS)-2- fluorotetrahyd...)
Affinity DataIC50: 1.02nMAssay Description:1. Serially 4×-diluted compounds (10 concentration points in total) were separately premixed with KRAS G12C-GDP (ICE, Kras 20191018) in a reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM706674(US20240383922, Example 7-4)
Affinity DataIC50: 1.02nMAssay Description:Compounds were tested for binding to GDP-loaded wild-type KRAS (WT), KRAS-G12C, KRAS-G12D, and KRAS-G12V in a 384-well assay format using a TR-FRET p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM706676(US20240383922, Example 7-6)
Affinity DataIC50: 1.09nMAssay Description:Compounds were tested for binding to GDP-loaded wild-type KRAS (WT), KRAS-G12C, KRAS-G12D, and KRAS-G12V in a 384-well assay format using a TR-FRET p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM706679(US20240383922, Example 7-9)
Affinity DataIC50: 1.22nMAssay Description:Compounds were tested for binding to GDP-loaded wild-type KRAS (WT), KRAS-G12C, KRAS-G12D, and KRAS-G12V in a 384-well assay format using a TR-FRET p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

Displayed 1 to 50 (of 2749 total ) | Next | Last >>
Jump to: